Chemotherapeutic Agents for Inhibiting Protein Synthesis
- Detailed Technology Description
- None
- *Abstract
-
The technology relates to Hippuristanol and its derivatives as inhibitors of eukaryotic ribosome recruitmentphase of translation initiation and their use as antiproliferative, chemotherapeutic agents or as adjuvant incombination therapy with cytotoxic agents. The patent application governs the utility of the compounds aschemosensitizing agents. Chemotherapy remains front line therapy for cancer. Chemosensitizers couldsubstantially improve clinical outcome and adverse effects of current antineoplastic agents. The world cancermarket was established estimated at $23 billion in 2004 and is expected to grow to $61 billion by 2011 with a CAGR of 14.7%
- Country/Region
- USA
For more information, please click Here
